#United States #gene therapy #Market Expansion #BioLife Solutions #Bothell

BioLife Solutions Reports Impressive Revenue Growth in 2025

BioLife Solutions, Inc., a prominent supplier of cell processing tools and services, has announced remarkable financial results for 2025, reflecting its commitment to enhancing the cell and gene therapy (CGT) sector. With a total revenue of $96.2 million for the year, up 29% from 2024, the company continues to build momentum following a transformative year marked by strategic initiatives.

Strong Revenue Metrics

During the fourth quarter of 2025, BioLife recorded a revenue of $24.8 million, showing a 20% increase compared to the same quarter in the previous year. These numbers highlight the effectiveness of its biopreservation media franchise, which is integral to the growing CGT market.

The CEO of BioLife, Roderick de Greef, expressed optimism about the company's performance. "2025 was a transformative year for BioLife. With the strategic divestiture that focused our operations and a streamlined cost structure, we are poised for continued growth in 2026 and beyond," he stated.

Financial Highlights

• - Gross Margin: BioLife's GAAP gross margin for Q4 2025 stood at 63%, slightly down from 66% in Q4 2024. The adjusted gross margin was 64%.
• - Net Income: The company reported a net income of $2.1 million for Q4 2025, a significant turnaround from a net loss of $1.2 million in the same period the previous year. This translates to $0.04 per share for shareholders, an improvement from the loss per share of $0.03.
• - Adjusted EBITDA: For Q4 2025, BioLife's adjusted EBITDA was approximately $6.9 million, accounting for 28% of total revenue, indicating strong operational efficiency.

Business Developments

In addition to robust financial results, BioLife's advancements in the CGT sector are noteworthy. Its biopreservation media is currently being utilized in about 250 ongoing clinical trials, commanding over 70% of the market share in the U.S. Moreover, the company anticipates the approval of seven additional products in the upcoming year, enhancing its portfolio and market presence.

The closure of the sale of evo, a subsidiary, for $25.5 million further strengthens BioLife's financial footing and allows it to focus on its core operations.

Looking Ahead

BioLife has set ambitious targets for 2026, forecasting revenues in the range of $112.5 million to $115.0 million, which would represent an additional growth of 17% to 20% from the prior year. The company has also emphasized its commitment to maintaining a gross margin in the mid-60% range and ensuring GAAP profitability.

As the CGT market expands with emerging therapies and continued support from biotech investments, BioLife Solutions is well-positioned to leverage its expertise and innovative technologies to drive further growth.

In summary, BioLife Solutions has demonstrated substantial progress in 2025, marked by strong revenue growth, strategic business maneuvers, and a solid outlook for the upcoming year. With an established market presence and anticipated product approvals, the company is poised for an exciting future.